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HIV-serodiscordant couples wishing to conceive often seek assisted reproduction, during which spermatozoa from infected men
are washed to minimize the risk of HIV transmission to partner and fetus. We sought to improve this method by adding a
microbicide, PPCM, as an HIV prophylactic. HIV-1 (BaL) inhibition by PPCM appears irreversible and independent of added
Ca2+. Without added Ca2+, PPCM (≤10mg/mL, ≤90min), a stimulus of Ca2+-dependent acrosomal loss, has no eﬀect on sperm
motility, forward progression, or acrosomal status. PPCM-treated (10mg/mL) sperm retain their ability to acrosome react when
Ca2+ is added. Sperm DNA integrity/function is unaﬀected by PPCM (≤10mg/mL). Adding PPCM (5mg/mL, 30min) to washing
media reduces infectivity (viral antigen p24 and RNA) of ex-vivo HIV-infected semen by 3-4 Logs compared with washing alone.
Sperm washing with appropriate extracellular Ca2+ levels and PPCM is signiﬁcantly more eﬀective than washing alone at reducing
HIV infectivity.
1.Introduction
There were approximately 33.4 million people worldwide
living with HIV in 2008; of these, 2.7 million were newly
infected. There were approximately 2.0 million AIDS-related
deaths in 2008 [1]. These statistics are substantially below
those seen during the apparent peak in infections in 1996.
At least part of the reason for the trend toward stabilization
of the AIDS epidemic and increased longevity of HIV-
infected individuals can be attributed to the beneﬁcial eﬀect
of antiretroviral therapy [1].
Decreased risk of viral transmission and the prospect
of increased longevity of the infected parent secondary
to the use of highly eﬀective antiretroviral therapy pose
fewer challenges for infected individuals of reproductive age
to have their own children. However, HIV infection may
impair fertility [2–4], prompting HIV-infected men and
womentoseekmedicalassistance(i.e.,AssistedReproductive
Technologies, or ART). Further, ART is the method of
choice for fertile serodiscordant couples trying to conceive;
it reduces the risk of HIV transmission associated with
unprotected sexual intercourse [5].
Providing ART to HIV-infected couples, particularly
serodiscordant couples where the man is infected, is prob-
lematic for health care providers. HIV is sometimes detected
in semen from infected men, even when they are receiving
antiretroviral therapy [6, 7]. Spermatozoa contaminated
with HIV can transmit virus to the uninfected woman and
to the child [2, 8]. Several states in the U.S. prohibit use of
semen from HIV-infected individuals for insemination [9].
Sperm washing has been advocated as a method to
reduce HIV transmission, in which motile spermatozoa are
separated from seminal plasma, nonsperm cells, and HIV [9,
10]. This method appears to be successful, with no reported
infections in multiple procedures carried out in somewhat
more than 2000 couples [11, 12]. This was, in large part,2 ISRN Obstetrics and Gynecology
the basis for California legislation that permits a sperm wash
to minimize HIV transmission during ART procedures for
serodiscordant couples [13, 14].
However, not all infected semen processed by sperm
washing canbeused. Duetothe natureofthe spermwashing
method, detectable HIV titers remain in 4–6% of washed
sperm samples [4, 12, 15, 16]. Reasons for this are not
entirelyclear,butmaybedue,atleastinpart,toviralbinding
to the sperm fraction.
For the most part, neither conventional HIV-1 CD4
receptors nor coreceptors (CXCR4 and CCR5) have been
found on human spermatozoa [10, 17, 18]. However,
several studies [17, 19, 20] have shown that HIV binds to
spermatozoa.Bindingappearsavid,sinceitsurvivesrepeated
washes by gradient centrifugation. Sperm-bound HIV is
infectious [17, 20].
Alternative receptors had been proposed to account for
HIV binding [19, 21]. Ceballos and coworkers found that
HIV-1binds to human spermatozoa through sperm surface
heparan sulfate receptors and remains infectious [20].
HIV binding, through alternative receptors or non-
speciﬁc mechanisms, may explain the failure of a sperm
wash to completely remove HIV from infected semen in
all instances. Further, at least some proponents of sperm
washing to reduce risk of HIV transmission during assisted
reproduction advise against its use with intracytoplasmic
sperminjection(ICSI).Thisrecommendationisbasedonthe
possibility that ICSI may introduce HIV into the oocyte as a
result of HIV attached to the sperm membrane [4, 22].
Addition of a safe antiviral compound may oﬀer some
advantages over sperm washing alone in minimizing the
risk of HIV transmission during ART. Ideally, an eﬀective
antiviralagentaddedatoraroundthetimeofspermwashing
should result in the following: (1) processed sperm samples
would contain no residual infectious HIV; (2) ICSI could
be used as an assisted reproductive technique in HIV-
serodiscordant couples with fewer concerns; (3) treatment
couldbeoﬀeredtoalargernumberofserodiscordantcouples
than possible with the conventional sperm wash protocol,
which is biased in favor of very low or undetectable initial
viral load [8, 12]; (4) the risk of viral infection of health care
providers who are in direct contact with infected samples
would be greatly reduced.
Non-antiretroviral compounds have been developed,
intendedforvaginaluse,topreventHIVtransmissionduring
sexual intercourse. These compounds, known generically as
microbicides, have advanced up to and including clinical
trials [23–26]. Many belong to a class of compounds known
as polyanions, one of which is a poly-acidic oligomer,
code-named PPCM (formerly known as Sulfuric Acid-
Modiﬁed Mandelic Acid, or SAMMA), developed [27–32]
by the TOPCAD Program at Rush University Medical Center
(Chicago,IL)andlicensedbyYasoBiotechnologies(Phoenix,
AZ).
Polyanions tested to date, including PPCM, are noncy-
totoxic, broad-spectrum antimicrobial agents, with activities
against sexually transmitted pathogens, including HIV-1,
HSV-1, HSV-2, papillomavirus, N. gonorrhoeae, and C.
trachomatis [27–29, 31, 33]. They act in part by interfering
with microbial binding to target cells via the heparan sulfate
(or similar) receptor [34]. PPCM may be, therefore, an
attractive candidate as a safe antiviral agent that could be
used as an HIV-1 preventive agent during ART.
However, many polyanions, including PPCM, are con-
traceptive [34–37]. These compounds would be appropriate
for ART only if their antimicrobial activities can be separated
from their contraceptive activities, and they have no adverse
eﬀects on sperm function and integrity.
Contraceptive activities of polyanions may be due, at
least in part, to their abilities to induce premature acrosomal
loss. Mechanistic studies have identiﬁed this as a Ca2+-
dependent process [30]. We thought that it may be possible
to separate contraceptive and antimicrobial activities of
PPCM through manipulation of extracellular Ca2+ levels.
The purpose of the present study was to examine the
feasibility of the use of PPCM to reduce infectivity of HIV-1
in infected semen used for ART. Results favor the utility
of PPCM for this purpose. Inhibition of HIV-1 (BaL) by
PPCM is at least partially irreversible and is independent
of added extracellular Ca2+. In the absence of added Ca2+,
sperm washing in the presence of PPCM substantially
reduces (3-4 Logs) viral titer of ex-vivo HIV-1 (BaL)-treated
whole human semen from healthy donors, as compared
with washing alone. This occurs without negatively aﬀecting
measures of sperm DNA integrity or sperm function,
including motility, forward progression, acrosomal integrity,
and DNA decondensation.
2.MaterialsandMethods
2.1. Materials. ISolate, a colloidal density gradient medium
for separation of spermatozoa from semen for use in
ART, was purchased from Irvine Scientiﬁc (Santa Ana,
CA). Quinn’s sperm wash medium was purchased from
SAGE In-Vitro Fertilization, Inc. (Trumbull, CT). RPMI-
1640 medium (RPMI) was from Irvine Scientiﬁc; a custom
preparation of RPMI to which Ca2+ had not been added
was also provided by Irvine Scientiﬁc. HIV-1 (BaL; lot
# 07283002), an expanded laboratory strain, was from
the Virology Quality Assessment Program (VQA), Rush
University Medical Center and was provided by the Clin-
ical Retrovirology Research Laboratory, Department of
Immunology and Microbiology, Rush University Medical
Center, under the direction of Dr. J. Bremer. Reagents for
immune complex disruption and ELISA determination of
HIV-1 antigen p24 (hereafter referred to as p24) levels,
and real-time reverse transcription-PCR determination of
HIV-1 RNA were obtained in kit forms from PerkinElmer
Life Sciences, Inc. (HIV-1 p24 ELISA Kit; Boston, MA)
and Abbott Molecular, Inc.(RealTime HIV-1 RNA assay;
Des Plaines, IL; m2000 RealTime-PCR-System), respectively.
Calcium ionophore A23187 was from EMD Biosciences, Inc.
(Calbiochem; La Jolla, CA). All other reagents were of the
highest quality commercially available.
PPCM is licensed under U.S. Patent 5,932,619 by Yaso
Biotechnologies (Phoenix, AZ). It is a poly-acidic oligomer
with molecular weight of approximately 1500Da and was
synthesized by Dr. S. Jain, University of Illinois HealthISRN Obstetrics and Gynecology 3
Sciences Center (Chicago, IL) under the direction of the
TOPCAD Program by reacting D,L-mandelic acid with
sulfuric acid under proprietary conditions. The sodium salt
was prepared by reacting the free acid with alcoholic NaOH,
yielding an oﬀ-white powder.
2.2. Human Subjects. Semen samples used for HIV infectiv-
ity, sperm motility, and acrosomal status assessment were
collected from pools of eight healthy donors (Rush Univer-
sity Medical Center) and ﬁve fertile donors (Andromedix
Laboratory) from whom informed consent was given,
according to the protocols approved by their respective Insti-
tutional Review Boards. For semen used in all experiments
except DNA testing the mean donor age was 35 (range = 26–
44) years. Semen was of generally high quality; mean semen
volume was 3.0 ± 0.24 (standard error of the mean; SEM,
N = 13) mL. Initial mean (with 90% conﬁdence limits)
values for sperm count, % motility, % forward progression,
and % viable spermatozoa were 83 (58.9–117.8; N = 11) ×
106/mL, 69 (64.3–73.6; N = 12)%, 78 (72.0–82.9; N = 12)%
and 90 (85.7–93.0; N = 12)%, respectively.
Semen used for SDFA and SDD testing was derived from
ﬁve donors of proven fertility, selected for the ability of their
spermatozoa to undergo DNA decondensation (96% ± 2%
SD) within 15 minutes of adding stimulus.
2.3. Semen Collection and Processing. Semen was collected
into sterile containers by self-masturbation. Samples were
allowed to stand at ambient temperature for one hour to
allow for liquefaction. Spermatozoa were separated from
seminal plasma by centrifugation through a discontinuous
gradientconsistingofequalvolumesof45%and90%ISolate
(Irvine Scientiﬁc) at 200×g for 20min. Spermatozoa at the
bottom of the gradient were resuspended in Quinn’s Sperm
Wash and washed by centrifugation at 200×g for 10min.
Unless otherwise noted, the sperm pellet was suspended in
medium(eitherBWWorRPMI),towhichCa2+ hadnotbeen
added, prior to further use.
2.4. Sperm Viability/Function Variables
2.4.1. Motility, Forward Progression, and Viability. Motility
measurements of 10μL samples were carried out under
light microscopy (200x) with a Neubauer hemacytometer
by standard operating procedures used by the Andrology
Laboratory of the Rush Centers for Advanced Reproductive
Care, Rush University Medical Center. Motile spermatozoa
were deﬁned as cells displaying any type (progressive, in-
place) of movement; spermatozoa passing through the ﬁeld
of vision were considered forwardly progressing. From 200–
400 spermatozoa were examined in at least 10 nonadjacent
ﬁelds. Motility was recorded as percentage of total sperma-
tozoa that were moving; forward progression was recorded
as the percentage of motile spermatozoa that was forwardly
progressive.
Sperm viability was measured with Eosin Y. Staining was
visualized by bright ﬁeld light microscopy (400x). Spermato-
zoa that stained green were considered viable; spermatozoa
that stained red were regarded as nonviable. Results were
recorded as the percentage of total spermatozoa that were
viable. Results for sperm motility, forward progression and
viability are presented as mean percentage of postwash
control values, together with SEM.
2.4.2. Acrosomal Status and Acrosomal Loss. Within the
context of this study, acrosomal loss refers to the disruption
ofthespermacrosomeinresponsetoatreatmentorchemical
entity. No inference is made as to whether this response is
identical to a physiological acrosome reaction, during which
the acrosome is also lost.
Spermatozoa recovered from ISolate gradient centrifu-
gation were resuspended in modiﬁed Biggers, Whitten
and Whittingham (BWW; [38]) medium (less albumin
and Ca2+). After incubations of washed spermatozoa with
10mg/mL PPCM or with medium alone for 15min at
ambient temperature, samples were placed onto 1mL of
11% (wt/vol) buﬀered Ficoll (containing 120mMNaCl and
25mMHEPES, pH 7.4), and centrifuged at 15,000g-min
(22◦Ct o2 4 ◦C). Supernatants were aspirated from the sperm
pellets,andthepelletswereresuspendedintomodiﬁedBWW
medium. The suspensions were recentrifuged at 1,000g-
min. The supernatants were aspirated, and the pellets were
resuspended in 1mL BWW medium. The latter washing step
was repeated, at which point, the PPCM concentration in
the supernatant, as measured by the absorbance at 266nm,
was undetectable. Details of sperm preparation have been
described [39, 40].
Sperm pellets obtained from the above procedure were
resuspended in BWW medium that contained 2.3mM
CaCl2.A f t e re q u i l i b r a t i o nf o r1 0 m i na t3 7 ◦C, acrosomal
loss was induced by addition of stimulus (PPCM or
calcium ionophore A23187). Fifteenmin after acrosomal
loss induction, spermatozoa were ﬁxed with buﬀered glu-
taraldehyde, smeared onto slides and stained with Rose
Bengal and Bismarck brown for acrosome visualization [30,
39]. Approximately 450 cells were scored per slide. Data
are expressed as means, with 90% conﬁdence limits, of
percentage of acrosomal loss induced.
2.4.3. Sperm DNA Fragmentation Assay (SDFA) and Sperm
DNA Decondensation (SDD) Test. The SDFA and SDD Test
were carried out at the Andromedix Laboratory, Woburn,
MA.TheSDDTestwasformerlyknownastheHumanSperm
Activation Assay (HSAA, [41]).
Experiments were conducted at ambient temperature.
Fresh semen samples were divided into aliquots as follows.
Controls. Semen was mixed with 2mL “nuclear isolation
medium” (NIM), consisting of 200mM sucrose, 2.4mM
MgCl2, 10mMTris-HCl, 5mMmaleic acid, pH 7.4, and
centrifuged at 1200×g for 10min to remove seminal plasma.
Sperm pellets were resuspended in 1.0mL of NIM (solvent
for PPCM), prior to the SDFA, or analysis in the SDD Test as
described by Brown et al. [41].
Treated Samples. Sperm pellets were resuspended in 1.0mL
of NIM containing PPCM (2mg/mL or 10mg/mL, ﬁnal4 ISRN Obstetrics and Gynecology
concentrations). After a 10min incubation, samples were
centrifuged at 1200×g for 5min; sperm pellets were resus-
pended in 1.0mL NIM and the suspension was recen-
trifuged. The ﬁnal pellets were either resuspended in 0.5mL
NIM and snap-frozen in liquid nitrogen prior to the SDFA,
or resuspended in 1.0mL NIM and kept overnight at 4◦C
prior to analysis in the SDD Test.
2.4.4. SDFA. The SDFA uses the same methodology as
the Sperm Chromatin Structure Assay [42]. The SDFA
utilizes Acridine Orange (AO) as a ﬂuorescent DNA probe
and employs ﬂow cytometry to measure the intensity of
ﬂuorescence. AO is a cell-permeant nucleic acid binding
dye that emits green ﬂuorescence when bound to double-
stranded (normal) DNA and red ﬂuorescence when bound
to single-stranded (damaged) DNA. For each sample, 5000
cells were measured and the ratio of red to total ﬂuorescence
(red + green) was calculated. This value, expressed as a
percentage, is the DNA Fragmentation Index (DFI). Each
assay was carried out in duplicate, which was averaged. All
averageddataforeachsemendonorweresubjectedtoarcsine
transformation prior to further analysis. Values are given
as means, with 90% conﬁdence limits. A DFI score of ≥30
indicates signiﬁcantly compromised DNA integrity. For this
study, DFI scores ≤15 were considered normal. A mean score
where 15 < DFI < 30, suggests a marginal loss of DNA
integrity due to treatment.
2.4.5. SDD Test. Samples (see above) were centrifuged at
1200×g for 10min and resuspended in permeabilization
medium for 5min. They were sequentially washed with
NIM containing bovine serum albumin, and treated for
one hour with Xenopus egg extract isolation medium
(XEIM; 10mMTris-HCl, 1.5mMMgCl2, 100mMKCl,
50mMdithiothreitol, pH 7.5). Sperm suspensions were
centrifuged at 1200×g for 10min, and the pellets were
suspended in XEIM to a ﬁnal cell concentration of
25 × 106 cells/mL. For each sample, 50,000 permeabilized
sperm were incubated in 25μLo fXenopus laevis egg extract,
to simulate the in vivo environment of the sperm nucleus
postfertilization. After 15min, an aliquot of the sperm-
extract mixture was placed on a slide, and 50–100 sperm
were scored with phase-contract microscopy in real time
duringa5minwindow.Thepercentageofspermundergoing
full decondensation was determined. The measurement of
full decondensation has been fully described by Brown et al.
[41]. Data were processed as described for the SDFA. Values
are presented as mean % fully decondensed spermatozoa,
with 90% conﬁdence limits.
2.5. HIV-1 Infectivity
2.5.1. Inhibition of HIV-1 (BaL) by PPCM: Eﬀect of Added
Extracellular Ca2+. PPCM at several concentrations ranging
f r o m0 . 1t o2 0 m g / m Lw a sa d d e dt oH I V - 1( B a L )s u s -
pensions (5.9 × 103 TCID50s/mL). Medium was RPMI-
1640, supplemented with glutamine, gentamycin, human
growth factor and interleukin-2, with or without added
Ca2+ (0.46mMCa(NO3)2–4(H2O)). After 1h at ambient
temperature, suspensions were diluted 1:100 with RPMI
(with or without added Ca2+), prior to inoculation into
peripheral blood mononuclear cell (PBMC) suspensions
(2.0 × 106 cells in 0.1mL). After 1h, PBMCs were washed
with fresh medium (containing added Ca2+)t or e m o v e
unbound virus and PPCM, and the PBMC suspensions were
incubated for 72 hours at 37◦C to allow for viral replication.
Viral p24 levels were measured by ELISA with reagents
provided in kit form by PerkinElmer Life Sciences, Inc.,
according to instructions provided by the vendor. Values
were quantiﬁed with a standard curve of HIV-1 p24 concen-
tration as a function of absorbance at 490nm. Intra- and
interassay coeﬃcients of variance are approximately 2.0%
and 10.0%, respectively. Data are expressed as means ± SEM.
The concentration of PPCM required for 50% inhibition
of p24 production (IC50 v a l u e ,o b t a i n e df r o mc u r v e sﬁ tt o
the data with TableCurve 2D; see Statistical Analysis) when
PPCMwasaddedtocompleteRPMIwascomparedwiththat
obtained when PPCM was added to medium without added
Ca2+.
2.5.2. Reversibility of HIV-1 Inhibition by PPCM. Inhibition
of viral replication by PPCM was compared under two
conditions, as follows: (1) PPCM at concentrations up to
13mg/mL was added to only HIV-1 (BaL), and incubated
for 1h, followed by a 1:100 dilution in RPMI, prior to
the suspension being inoculated onto PBMCs. Subsequent
washing medium changes and incubation of PBMCs to allow
forviralreplicationwerecarriedoutintheabsenceofPPCM.
(2) PPCM at concentrations up to 1mg/mL was added to
viral suspensions, incubated for 1h, and inoculated onto
PBMCs that contained the same concentrations of PPCM.
Washing and medium changes also contained PPCM (i.e.,
PPCM was present throughout the entire procedure). The
incubation medium (RPMI) contained added Ca(NO3)2–
4(H2O). Other experimental conditions and measurement
of p24 levels were the same as described above for eﬀect
of added extracellular Ca2+.T h eI C 50 value of PPCM when
PPCM was added to only virus was compared with that
obtained when PPCM was present throughout the viral
infection and replication.
2.5.3. Inhibition by PPCM of HIV-1 Infectivity When HIV Is
Added to Whole Semen. Neat fresh semen pooled from ﬁve
donors (11.3mL) was added to an equal volume of HIV-
1 (BaL) inoculum (5 × 105 TCID50s/mL). Total inoculum
and total number of spermatozoa were 5.65 × 106 TCID50s
and 1.07 × 109 cells, respectively. After 30min at ambient
temperature, small samples were taken, diluted and added
directly to PBMC suspensions (unprocessed control). One
volume of either 0.9% saline (processed control) or PPCM
stock solution (20mg/mL in 0.9% saline, sterile-ﬁltered)
was added to three volumes of the semen/viral suspension.
These mixtures were incubated for 45min at ambient
temperature. Spermatozoa were isolated by centrifuging
the mixture through sperm ISolate preparation gradients
(200×g, 25min). Gradients were aspirated. The sperm
pellets and residual supernatants (total volume approx.
0.2mL) were resuspended in 1mL RPMI without addedISRN Obstetrics and Gynecology 5
Ca2+ and centrifuged at 200×g for 10min. Sperm pellets
(approximately 0.2mL) were used as the viral inoculum,
and added to PBMC suspensions. After 1h, PBMCs were
washed to remove unbound virus, spermatozoa and PPCM,
and incubated for 72h in Ca2+-replete RPMI to permit viral
replication. At this time, a portion of each sample was taken
for p24 measurement (see above).
The remainder of each sample was stored at −80◦C until
being used for viral RNA measurements by real-time reverse
transcription PCR (m2000 Real Time HIV assay), with
automated RNA preparation (m2000sp) and measurement
(m2000rt)carriedoutasinstructedbythemanufacturer.The
assaywasstandardizedagainstaviralstandardfromtheVQA
Program (see Materials). The assay is designed to achieve
an interassay standard deviation of ≤0.25logcopies/mL at
concentrationsrangingfrom500to5 × 106 copies/mL.Data
(copies/mL viral RNA) are expressed as means ± SEM.
2.6.StatisticalAnalysis. Fordatarequiringeitherlogarithmic
(sperm count) or arcsine transformation (frequencies; initial
sperm motility, forward progression, viability; acrosomal
loss), results are expressed as means, with 90% conﬁdence
limits [43]. Other data are expressed as means, ± SEM.
Eﬀects of PPCM dose and duration of exposure were
evaluated with two-way analysis of variance. Diﬀerences
among individual treatment groups were assessed with the
Newman-Keuls multiple range test [44]. Data from dose
response experiments were best ﬁt to curves by regression
analysis with TableCurve 2D curve-ﬁtting software (version
5; SPSS Statistical Software, Chicago, IL), from which
appropriate constants (e.g., IC50; that concentration of
agent required for 50% inhibition of HIV infectivity) were
calculated. All values are considered signiﬁcantly diﬀerent
at the 0.05 level of conﬁdence; P>. 10 is considered not
diﬀerent.
3. Results
3.1. Inhibition of HIV Infectivity by PPCM Is Independent of
Added Ca2. Dose responses of HIV infectivity as a function
of PPCM concentration (from 1 × 10
−5 to 6.7mg/mL) were
measuredinthepresenceandabsenceofaddedCa2+.Inthese
experiments, all samples contained Ca2+ during the 72h
incubationofPBMCstoallowforviralreplicationofinfected
cells.Ca2+ isessentiallywithouteﬀectontheabilityofPPCM
to reduce HIV infectivity. The IC50 (90% conﬁdence limits
= 33.7–66.3% inhibition) for samples incubated in Ca2+-
r e p l e t eR P M Ii s2 4 μg/mL. In Ca2+-deﬁcient medium, the
IC50 (46.8–53.2% inhibition) is 39μg/mL (Figure 1).
3.2. HIV Inhibition by PPCM Is Not Reversible by Dilution.
Dose response of HIV infectivity as a function of initial
PPCM concentration (from 1 × 10
−5 to 13.3mg/mL) was
measured in samples in which PPCM concentrations were
maintained throughout the experimental procedure (viral
incubation, inoculation onto PBMCs, wash to remove free
virus and incubation of infected PBMCs to permit viral
replication). This was compared with the dose-response
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Figure 1: Inhibition of HIV-1 BaL by PPCM is independent of
added Ca2+. Values are levels of p24 (pg/mL); Errors are SEM
(N = 3). Media contained 100mg/mL Ca(NO3)2–4(H2O), either
throughout the procedure (added Ca2+) or only after washing
PBMCs to remove unbound virus and PPCM (i.e., during PBMC
incubation to allow for viral replication). Data were ﬁt to transi-
tional curves described by the general equation for a log-normal
cumulative distribution, Y = a +0 .5b(erf)c(−ln(x/c)/(20.5d)). In
the absence of added Ca2+, a = 2.38408, b = 491.6185, c = 0.03921,
and d =− 0.82000 (r2 = 0.9999); in the presence of added Ca2+,
a = 0.00853, b = 497.99248, c = 0.02378, and d =− 0.76421
(r2 = 0.9995). The IC50 values of PPCM with and without added
Ca2+ are 24 (90% conﬁdence limits = 33.7–66.3% inhibition) and
39 (46.8–53.2% inhibition) μg/mL, respectively.
measured in samples in which PPCM-treated virus was ﬁrst
diluted 1:100 prior to inoculation onto PBMCs. In the latter
samples, medium used for procedures subsequent to initial
viral exposure to PPCM was PPCM-free.
Dilution and subsequent removal of PPCM by washing
has essentially no eﬀect on the ability of PPCM to inhibit
HIV infectivity (Figure 2). When the initial concentration
of PPCM is maintained throughout all procedures (no
dilution), the IC50 (33.7–66.3% inhibition) for PPCM is
23μg/mL. The IC50 (90% conﬁdence limits = 48.6–51.4%
inhibition) for PPCM when added only to viral suspensions,
followed by dilution, is 36μg/mL.
3.3. PPCM Has Minimal Eﬀect on Sperm Motility and
Viability. Sperm exposure to PPCM at concentrations up
to 10mg/mL for periods up to 90min has little eﬀect on
sperm motility, forward progression or viability (Figures
3(a)–3(c)). Two-way ANOVA showed no eﬀect of either
PPCM concentration or duration of exposure to PPCM on
motility (F(2,30) = 1.36 and F(4,30) = 1.43, resp.; P>. 10)
or forward progression (F(2,30) = 1.48 and F(4,30) =
1.63, resp.; P>. 10). Similarly, there is no eﬀect of PPCM
concentration on sperm viability (F(2,30) = 1.67, P>. 10),6 ISRN Obstetrics and Gynecology
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Figure 2: Evidence for irreversibility of HIV-1 BaL by PPCM.
PPCM was added to either virus and PBMCs (present during viral
infectionandreplication)attheindicatedconcentrations,oronlyto
virus, followed by a 1:100 dilution prior to inoculation into PBMC
suspensions. Other conditions are presented in Section 2. Values
are levels of viral p24 (pg/mL). Errors are SEM. For incubations
in which PPCM was present throughout the experiment at the
indicated concentrations, data were ﬁt to transitional curves
described by the general equation for a log-normal cumulative
distribution, Y = a+0.5b(erf)c(−ln(x/c)/(20.5d)); a = 0.00853042,
b = 497.99247, c = 0.023779, and d =− 0.764206 (r2 =
0.9995). For incubations in which PPCM was added only to virus,
followed1hlaterbya1:100dilutionbeforeinoculationintoPBMC
suspensions, data were ﬁt to a curve described by the equation
Y = aexp(−x/b), where a = 498.29049 and b = 0.0526604 (r2 =
0.9995). IC50 values of PPCM when added only to virus and when
present throughout the procedure were 36 (48.6–51.4% inhibition)
and 23 (33.7–66.3% inhibition) μg/mL, respectively.
although a small eﬀe c t( 1 1 %r e d u c t i o na t9 0m i ne x p o s u r e
to 10mg/mL PPCM) of duration may exist (F(4,30) = 5.03,
P<. 01).
3.4. Acrosomal Status Maintained after Sperm Treatment
with PPCM in Absence of Added Ca2+. Acrosomal status
of sperm suspensions treated with 10mg/mL PPCM for
15min in BWW medium without added Ca2+ is simi-
lar to control spermatozoa (no PPCM treatment) simi-
larly processed, when spermatozoa from both groups are
subsequently washed and added to Ca2+-replete medium
(detailed protocol presented in Section 2). Percentage of
PPCM-treated spermatozoa without acrosomes is 19 (90%
conﬁdence limits = 18.6–20.0)%. This is essentially the same
as the percentage (19 (17.7–21.2)%) of control spermatozoa
without acrosomes (P>. 10, Newman-Keuls multiple range
test). Acrosomal loss increases to a similar extent in both
PPCM-treated and control samples in response to stimuli
(P>. 10, Newman-Keuls multiple range test). Percentage of
spermatozoa without acrosomes in response to a maximally
stimulating concentration of calcium ionophore A23187 is
32 (31.0–32.5)% and 32 (30.9–32.9)% for PPCM-pretreated
and control spermatozoa, respectively. Percentage of sper-
matozoa without acrosomes in response to 0.25μg/mL
PPCM (concentration required to induce 50% maximal
acrosomalloss[30])is27(26.3–27.6)%and27(26.6–27.7)%
for PPCM-pretreated and control spermatozoa, respectively
(Figure 4).
3.5. PPCM without Eﬀect on Sperm DNA Fragmentation
or Stimulus-Induced DNA Decondensation. Pretreatment of
spermatozoa with either 2mg/mL or 10mg/mL PPCM
had no eﬀect on sperm DNA fragmentation (Figure 5(a)).
Fragmentation in spermatozoa pretreated with PPCM is
essentially the same as that in spermatozoa pretreated with
only medium (F(2,9) = 2.80; P>. 10). Mean DFI for
negative control spermatozoa, spermatozoa treated with
2mg/mL PPCM and spermatozoa treated with 10mg/mL
PPCM are 6 (90% conﬁdence limits = 4.5–6.6), 7 (2.9–12.4)
and 9 (6.1–13.3), respectively.
A similar lack of eﬀect of PPCM was noted on the
ability of DNA from permeabilized spermatozoa to decon-
dense in response to Xenopus laevis egg extract (F(2,8) =
0.59; P>. 10). Mean percentage of control spermatozoa,
spermatozoa pretreated with 2mg/mL PPCM, and sperma-
tozoa pretreated with 10mg/mL PPCM that showed full
decondensation in response to egg extract are 96 (95.0–
97.0)%, 98 (87.2–99.5)%, and 96 (95.5–96.9)%, respectively
(Figure 5(b)).
3.6. Infectious Viral Titer of Whole Semen with Simulated
HIV Infection Is Reduced by PPCM. Following incubation
with HIV-1 (BaL) for 30min, whole semen was treated
with either 5mg/mL PPCM or with an equal volume of
medium (without added Ca2+), and incubated at ambi-
ent temperature for 45min (see Section 2 for complete
description of experimental protocol). In samples without
PPCM, gradient centrifugation, followed by two washes
by resuspension and recentrifugation, reduced the initial
viral titer by approximately 92%, as measured by viral p24
l e v e l s .Am u c hg r e a t e rr e d u c t i o ni nv i r a lt i t e ri se ﬀected by
pretreatment with PPCM. PPCM further reduces viral p24
levels by approximately 3 Logs, (99.94% reduction, to 0.04 ±
0.03 (SEM) ng/mL) as compared with samples subjected to
only centrifugation.
Greater reduction of viral titer by PPCM is obtained
w h e nt i t e ri se x p r e s s e da sv i r a lR N A( Figure 6(b)). Similar
to p24 concentrations, gradient centrifugation followed by
washing (without PPCM) reduces viral RNA concentration
by 92% (to 4.91 ± 0.055 × 105 copies/mL). Viral RNA
is further reduced by approximately 4.4 Logs (to 20 ±
3copies/mL) by pretreatment with PPCM.
Reductions in viral titer from that observed in the
unprocessed, HIV-incubated semen produced by either
sperm washing or PPCM pretreatment followed by sperm
washing are signiﬁcant (P<. 01, Newman-Keuls multiple
range test). Diﬀerences are signiﬁcant whether viral p24 or
viral RNA concentration is the dependent variable.ISRN Obstetrics and Gynecology 7
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Figure 3: Lack of eﬀect of PPCM on sperm motility, forward progression and viability. Washed spermatozoa were exposed to PPCM
at diﬀerent concentrations and durations of exposure, as indicated. The experimental protocol for these experiments is presented in
Section 2. (a): Neither concentration nor duration of treatment with PPCM aﬀects sperm motility. Values are the means ± SEM of duplicate
determinations from each of 3 donors (number of donors represents sample size). Two-way ANOVA shows no eﬀect of either duration
of treatment (F(4,30) = 1.43; P>. 1) or dose of PPCM (F(2,30) = 1.36; P>. 1) after exposure to 10mg/mL PPCM for up to 90min.
Similarly, one-way ANOVA shows no overall treatment eﬀect of PPCM (F(15,32) = 0.99; P>. 1 ) .( b ) :N e i t h e rc o n c e n t r a t i o nn o rd u r a t i o n
of exposure aﬀects sperm forward progression. Values are the means ± SEM of duplicate determinations from each of 3 donors (number of
donors represents sample size). Two-way ANOVA shows no eﬀect of either duration of treatment (F(4,30) = 1.63; P>. 1), or concentration
of PPCM (F(2,30) = 1.48; P>. 10). Similarly, one-way ANOVA shows no eﬀe c to ft r e a t m e n t( F(15,32) = 0.85; P>. 1). (c): Duration
of exposure to, but not dose of PPCM has small eﬀect on sperm viability. Data are expressed as percentage of postwash control viability,
as described in Section 2. Values are the means ± SEM of duplicate determinations from each of 3 donors (number of donors represents
sample size). Two-way ANOVA shows an eﬀect of duration of treatment (F(4,30) = 5.03; P<. 005), but not concentration of PPCM
(F(2,30) = 1.67; P>. 1); no interactive eﬀect of dose and exposure time is seen. The Newman-Keuls multiple range test indicates essentially
no eﬀect among treatment groups (P>. 05). One-way ANOVA shows an overall eﬀect of treatment (F(15,32) = 2.054; P<. 05). Viability
at 90min for samples exposed to either 5mg/mL or 10mg/mL PPCM is reduced by 11% as compared with the untreated sample at 90min
(P<. 05, Newman-Keuls multiple range test).8 ISRN Obstetrics and Gynecology
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Figure 4: Acrosomal status and ability to respond to acrosomal
loss stimuli are maintained after PPCM pretreatment. Motile
spermatozoa harvested from pooled semen were resuspended in
Ca2+-deﬁcient medium and treated with 10mg/mL PPCM for
15min, followed by gradient and diﬀerential centrifugation to
reduce PPCM concentration to undetectable levels. Spermatozoa
were resuspended in Ca2+-replete medium and acrosomal status
was evaluated before and after adding stimuli (PPCM or A23187)
of acrosomal loss. Experimental details are provided in Section 2.
Values are given as mean percentage of spermatozoa lacking
acrosomes; error bars are 90% conﬁdence limits. A−CValues with
diﬀerent letter designations are diﬀerent (P<. 001, Newman-Keuls
multiple range test).
4. Discussion
The present data support the utility of PPCM as an eﬀective
compound for use in ART to further reduce the risk of
HIV transmission. Data collected in other investigations for
this and similar compounds suggest that PPCM should be
relatively safe for use in ART, and should be eﬃcacious
in reducing infectivity of HIV (laboratory strains, clinical
isolates and diﬀerent clades) and several other sexually
transmitted pathogens in vitro [27, 29, 33, 36, 45–50].
Contraceptive activity of PPCM is believed to be due
to its ability to induce premature acrosomal loss; this eﬀect
requires physiological concentrations of extracellular Ca2+
[30]. Acrosomal integrity can be maintained in the presence
of PPCM only in the absence of added extracellular Ca2+.
It was important to demonstrate that PPCM retains its
inhibitory activity against HIV in a Ca2+-independent man-
ner. The present study has shown that the dose-response of
PPCM-induced inhibition of HIV infectivity is independent
of added Ca2+ (Figure 1).
Ideally,inhibitionofHIVbyPPCMwouldbeirreversible,
or at least pseudoirreversible. This allows for removal of
all or most of the agent after viral inactivation, which,
in turn, minimizes possible untoward side eﬀects on cel-
lular elements of the fertilization process and subsequent
embryonic development. PPCM-induced viral inhibition is
at least partially irreversible, since the dose-response of HIV
inhibition is unaﬀected by a 1:100 dilution of PPCM after
initial interaction with the virus (Figure 2).
Not all mechanisms of HIV inhibition by PPCM are
clearly understood. Part of the eﬀect may be due to
inhibition of viral entry. This occurs by preventing the
interaction of the positively charged V3 loop of viral gp120
with negatively charged coreceptors (e.g., heparan sulfate
or similar) on target (host) cells [51]. Studies with other
polyanionic microbicides (e.g., cellulose sulfate, polystyrene
sulfonate, cellulose sulfate phthalate) suggest that relatively
high concentrations of these agents may cause gp41 six-
helix bundle formation, viral disintegration and rapid loss
of infectivity [52]. The loss of viral integrity suggests an
irreversible mechanism of action. The work of Mesquita and
coworkers [33] suggests possible irreversible inhibition of
HIV-1(BaL)andHIV-1(RF)infectivityafterpretreatmentof
immobilized virus with PPCM followed by washing, Further,
a structural variant of PPCM inhibits HIV-1 (IIIB) and HIV-
1 (BaL) in an irreversible or pseudoirreversible manner [51].
These data are in agreement with the present study.
High concentrations of PPCM (25mg/mL) are relatively
noncytotoxic toward spermatozoa [27], as measured by
al a c ko fe ﬀect on sperm motility following short-term
exposure (Sander-Cramer test for spermicidal activity). We
have conﬁrmed and extended these studies by measuring
sperm motility, forward progression and sperm viability
after exposure to PPCM at concentrations as high as
10mg/mL for periods up to 90min (Figure 3). No eﬀect
was observed on sperm motility or forward progression.
A small, but signiﬁcant eﬀe c to fd u r a t i o no fe x p o s u r eo n
sperm viability was noted. The physiological signiﬁcance
of the latter ﬁnding is unclear, since no concentration-
dependent eﬀect was observed. The small eﬀect of duration
of exposure could reﬂect a small time-dependent decrease
in viability, independent of the presence of PPCM. These
data suggest that concentrations of and duration of exposure
to PPCM that should be eﬃcacious against HIV-1 have no
substantial eﬀect on sperm viability or selected aspects of
sperm function.
Earlier studies showing PPCM-induced acrosomal loss
as a Ca2+-dependent process, dependent upon physiolog-
ical concentrations of extracellular Ca2+ (ED50 approx.
0.08mM), were carried out with PPCM at concentrations
in the sub- μg/mL to μg/mL range [30]. The present study
examined whether these observations could be extended to
PPCM when used at concentrations several orders of mag-
nitude higher (mg/mL range). It was important to evaluate
whether previous exposure to PPCM aﬀected subsequent
ability of spermatozoa to undergo acrosomal loss in response
to stimulus.
Spermatozoa in Ca2+-deﬁcient medium were pretreated
with a high (10mg/mL) concentration of PPCM, washed
to reduce PPCM to nondetectable levels, and resuspended
in Ca2+-replete medium. Under these conditions, acrosomal
status is maintained at control levels in the absence of
stimulus. Further, similar to that of control samples, PPCM-
treated spermatozoa respond to acrosomal loss stimuli,
namely calcium ionophore A23187 and PPCM (Figure 4).ISRN Obstetrics and Gynecology 9
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Figure 5: PPCM is without eﬀe c to ns p e r mD N Af r a g m e n t a t i o na n dd e c o n d e n s a t i o no fs p e r mD N Ai nr e s p o n s et os t i m u l u s .T h es p e r m
DNA fragmentation assay (SDFA) and sperm DNA decondensation (SDD) test were carried out as described in Section 2.( a ) : Data for the
SDFA were expressed as percentage Defragmentation Index (DFI), deﬁned as the ratio of red ﬂuorescence to total ﬂuorescence (red plus
green) after staining with acridine orange. Processed samples to which PPCM were not added are designated as Negative Controls. Data for
a semen sample with a known high level of sperm DNA fragmentation are included as a reference, designated as Positive Control. Values are
given as means; error bars represent 90% conﬁdence limits. One-way ANOVA (excluding the Positive Control) showed no eﬀect oftreatment
(F(2,9) = 2.80; P>. 10). (b): For the SDD test, fully decondensed spermatozoa are presented as a percentage of total spermatozoa. Error
bars are 90% conﬁdence limits (N = 3−−5). Samples to which PPCM were not added are designated as Negative Controls. Data for a semen
sample with a known compromised DNA decondensation are included as a reference; designated as Positive Control One-way ANOVA
(excluding the Positive Control) shows no eﬀect of PPCM treatment on sperm DNA decondensation (F (2,8) = 0.59; P>. 1).
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Figure 6: PPCM decreases infectivity of semen infected in vitro with HIV. Details of treating whole semen with HIV-1 (Bal) followed by
PPCM exposure and measurement of viral titer after culturing in PBMCs are presented in Section 2. Data are reported as mean viral titer
(ng/mL of p24, (a): or copies/mL viral RNA, (b)) for each condition (note Log scale). Error bars are SEM (N = 3). A−CValues with diﬀerent
letter designations are diﬀerent (P<. 01, Newman-Keuls multiple range test).
As a stimulus of acrosomal loss (in the presence of added
extracellular Ca2+), PPCM was used at a concentration
(0.25μg/mL) predicted to induce 50% maximal acrosomal
loss [30]. Approximately 60% maximal loss was noted, in
s p e r m a t o z o ap r e t r e a t e dw i t hP P C Ma sw e l la si nc o n t r o l
spermatozoa subjected to the same protocol (washing by
centrifugation). The slight increase in acrosomal loss over
that predicted may reﬂect an increased fragility of the
acrosomes due to the experimental protocol of repeated
centrifugationandresuspension.Thedatasuggestthatunder10 ISRN Obstetrics and Gynecology
appropriate conditions, prior treatment with relatively high
concentrations of PPCM is without eﬀect on acrosomal
status.
In order for PPCM-treated sperm to be used in ART
procedures, it is important to establish that PPCM does
not negatively aﬀect sperm DNA integrity and/or sperm
functions required for postfertilization restructuring of the
sperm nucleus, once inside the egg. To test this, PPCM-
treated sperm were analyzed with two tests: the Sperm DNA
Fragmentation Assay (SDFA)/Sperm Chromatin Structure
Assay (SCSA), a sperm structure assay used to measure DNA
integrity [42]; and the Sperm DNA Decondensation (SDD)
Test; a sperm function test used to measure overall sperm
nuclear integrity [41]. Both the SCSA and SDD Test have
clinical relevance in predicting live birth outcome [41, 42,
53]. Normal scores in PPCM-treated sperm for both tests
support the use of PPCM-washed sperm in ART.
The two tests were also used to test the hypothesis
that the polyanionic nature of PPCM might allow the
sperm nuclear membrane to be compromised through ionic
interactions with either protamines or histones within the
sperm chromatin. Protamine packaging greatly condenses
the DNA, resulting in lower accessibility to DNA-damaging
agents.Ifthisisincomplete,exposedDNAmaybevulnerable
todamagefromagentsinthesurroundingenvironment[54].
PPCM-induced interference with protamine-DNA interac-
tion would be reﬂected as highly fragmented DNA, and/or
delayed sperm DNA decondensation/nuclear swelling, as
detected with the SDFA and SDD Test, respectively. How-
ever, PPCM (≤10mg/mL) has no eﬀect on either sperm
DNA fragmentation (Figure 5(a))o rD N Ad e c o n d e n s a t i o n
(Figure 5(b)).Thesedataareconsistentwithstudiesinwhich
PPCM displayed no mutagenic activity, as measured by the
Ames test [31]. Further, they support the safety of using
PPCM-treated washed spermatozoa in ART to reduce risk of
HIV infection.
The ability of PPCM to inhibit HIV infectivity in vitro
is well-documented [27, 28, 31, 49]. PPCM prevents HIV
infectionofseveraltypesoftargetcellsinvitro.Italsoinhibits
HIV transmission via dendritic cells [31]. The present study
extended these studies by evaluating the ability of PPCM to
inhibit HIV associated with whole semen.
Infected semen was simulated by incubating uninfected
semen with a high titer of HIV-1 (BaL). This, rather
than semen from HIV-infected men, was used to permit
suﬃciently high viral titers (particularly after washing by
gradient centrifugation) to accurately quantify eﬃcacy of
PPCM combined with sperm washing beyond that eﬀected
by washing alone. With this method, viral titers were
detectable even after 3 to 4-Log reductions.
Sperm washing by gradient and diﬀerential centrifu-
gation reduced initial viral titer by somewhat over 90%,
whether measured by viral p24 or RNA levels (Figures
6(a) and 6(b)). The method of sperm processing in the
present study is similar to that used clinically by Pe˜ na
and coworkers to reduce viral titers in semen from HIV-
infected men [5]. The relatively ineﬃcient removal of virus
suggests that washing alone may not be an optimal method
to completely remove high levels of viral contamination; this
isalsosuggestedbyworkpresentedinareviewbyEnglertand
coworkers[8].Thesedataareinagreementwithotherstudies
showing persistence of HIV in some samples after washing
[4, 16].
Removalofsolublecontaminationbywashingusedinthe
present study is more eﬃcient than removal of HIV. Concen-
tration of PPCM, for example, is reduced from 10mg/mL
to less than 0.1μg/mL (limit of detection). Although the
present study does not speciﬁcally address sperm binding of
HIV, the data showing only a 90% reduction in viral titer by
washing alone (Figure 6) are consistent with HIV binding to
spermatozoa, described in other studies [17, 19, 20].
Treatment of HIV-spiked semen with PPCM substan-
tially reduced viral titer. Levels of p24 in samples treated
withPPCM,followedbywashingbygradientanddiﬀerential
centrifugations were reduced by 3 Logs, as compared with
p24 levels measured after washing alone (Figure 6(a)).
Reduction of viral RNA (>4 Logs, as compared with
washing alone) was greater than that of p24; RNA levels
in the presence of PPCM were near the limit of detection
of the assay. Since production of structural and regulatory
RNA species precedes the production of structural proteins,
these data suggest that RNA levels may be more sensitive
than p24 levels to inhibition by at least some antiviral agents.
In some instances, the release of p24 antigen can continue
to occur even though HIV mRNA transcription and the
production of infectious virus particles is inhibited [55].
Wintersetal.[56]suggestthattheuseofproteinssuchasp24
to measure viral replication could obscure the eﬀectiveness
of an antiviral agent that primarily aﬀects the transcription
of certain types of viral RNA or DNA. Increased eﬃcacy of
PPCM when measured by viral RNA as compared with p24
measurements is consistent with mechanisms of inhibition
of HIV infectivity in addition to inhibition of viral binding
to target cells.
The present data show that PPCM can interact with and
inactivate HIV associated with spermatozoa. Although these
studies were restricted to a laboratory strain (BaL), results
can likely be extended to other strains as well as clinical
isolates, since PPCM is active against several HIV strains and
isolates [28, 29, 31, 33]. Whether interaction of HIV with
spermatozoa in vitro is similar to that observed in semen
from HIV-infected individuals is unknown. Additional work
is required to demonstrate eﬃcacy of PPCM against sperm-
associated HIV from HIV-infected men.
In spite of proven in vitro eﬃcacy of polyanionic
compounds against several sexually transmitted pathogenic
microbes, including HIV-1, none has successfully completed
Phase 3 clinical eﬃcacy trials for HIV prevention [57–60].
Reasons for this apparent failure are not entirely clear. Part
of the failure could be due to the trials themselves [58, 61].
Regardless of the reason for the failure of clinical trials,
the eﬃcacy of these compounds to prevent HIV and other
microbial infections in vitro make them attractive candidates
for reducing the risk of viral transmission from infected
semen when processed in vitro for ART. The present study
providesfavorabledatafortheuseofPPCMforthispurpose.
PPCM could also be useful for preventing transmission of
other infections that coexist in HIV-infected individuals,ISRN Obstetrics and Gynecology 11
including hepatitis C [62]. Other polyanions are active in
preventing binding of hepatitis C to target cells [63], possibly
by antagonizing interactions with heparan sulfate, or other
heparin-like moieties on the cell surface [64].
Under appropriate conditions (i.e., use of Ca2+-deﬁcient
media, washing to remove compound after treatment prior
to using Ca2+-replete media), PPCM can eﬀectively reduce
HIV infectivity by several orders of magnitude without
adversely aﬀecting sperm function. Although all data col-
lected to date support the utility of PPCM as an antiviral
prophylactic, additional work is clearly indicated to validate
its use for ART. Successful validation and conﬁrmation
of lack of embryotoxicity of this method could create
a new standard of care regarding the use of PPCM or
other polyanionic microbicides to reduce infectivity of, or
otherwise inactivate, one or more viruses (including HIV)
that may be present in semen used in ART.
PPCM and other polyanionic compounds have broad-
spectrum activities against a number of sexually transmitted
pathogens (see Section 1). Our long-term goal will be to
determine if PPCM can reduce the risk of transmission
of one or more of several sexually transmitted microbes,
in addition to HIV, when spermatozoa used for ART are
routinely treated in vitro with this agent as part of a washing
procedure based on data presented in the present study.
5. Conclusions
We examined the feasibility of improving the method of
sperm washing used to reduce risk of HIV transmission
during ART by adding PPCM, a microbicide for reducing
sexually transmitted infections. A method is described
in which PPCM, with sperm washing, is 3-4 orders of
m a g n i t u d em o r ee ﬃcacious than washing alone, in reducing
HIV infectivity, without aﬀecting sperm.
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